<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "http://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.1" specific-use="sps-1.9" article-type="editorial" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">Th96xTn5XmMhcN4ZbyHDp4v</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2024001100207</article-id>
      <article-id pub-id-type="other">00207</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20240652</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Minieditorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Ades&#227;o, Conformidade e Persist&#234;ncia no Tratamento do Colesterol Alto</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-1027-6954</contrib-id>
          <name>
            <surname>Martinez</surname>
            <given-names>Tania L. R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <aff id="aff1">
          <label>1</label>
          <institution content-type="orgname">A Benefic&#234;ncia Portuguesa de S&#227;o Paulo</institution>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">BP - A Benefic&#234;ncia Portuguesa de S&#227;o Paulo, S&#227;o Paulo, SP &#8211; Brazil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1"><label>Correspond&#234;ncia:</label><bold>Tania Martinez</bold> &#8226; Rua Comandante Ismael Guilherme, 358 - Jardim Lusit&#226;nia. CEP <postal-code>04031-120</postal-code> - S&#227;o Paulo, SP - Brasil E-mail: <email>tamar@uol.com.br</email></corresp>
      </author-notes>
      <pub-date publication-format="electronic" date-type="pub">
        <day>20</day>
        <month>01</month>
        <year>2025</year>
      </pub-date>
      <pub-date publication-format="electronic" date-type="collection">
        <year>2024</year>
      </pub-date>
      <volume>121</volume>
      <issue>11</issue>
      <elocation-id>e20240652</elocation-id>
      <history>
        <date date-type="received">
          <day>03</day>
          <month>10</month>
          <year>2024</year>
        </date>
        <date date-type="rev-recd">
          <day>16</day>
          <month>10</month>
          <year>2024</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xml:lang="en" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave</title>
        <kwd>Ades&#227;o</kwd>
        <kwd>Conformidade</kwd>
        <kwd>Persist&#234;ncia</kwd>
        <kwd>Colesterol</kwd>
        <kwd>Tratamento</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="4"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>A falta de ades&#227;o aos medicamentos para redu&#231;&#227;o do colesterol continua sendo uma quest&#227;o cr&#237;tica no gerenciamento do risco cardiovascular. Apesar dos avan&#231;os no tratamento, muitos pacientes n&#227;o seguem seus regimes prescritos, levando a maiores riscos de ataque card&#237;aco, derrame e outros eventos cardiovasculares. Conforme descrito no estudo dos ABC Cardiol,<sup><xref ref-type="bibr" rid="B1">1</xref></sup> os desafios de ades&#227;o na popula&#231;&#227;o brasileira ilustram um problema global. No entanto, existem v&#225;rias estrat&#233;gias promissoras para aumentar a ades&#227;o, incluindo o envolvimento ativo de farmac&#234;uticos e a distribui&#231;&#227;o de medicamentos em volumes maiores por meio de sistemas de sa&#250;de p&#250;blicos ou privados.</p>
    <p>A ades&#227;o &#224; medica&#231;&#227;o, ou o grau em que os pacientes seguem seus regimes prescritos, &#233; fundamental para atingir resultados de sa&#250;de ideais em condi&#231;&#245;es cr&#244;nicas como colesterol alto. A ades&#227;o &#233; a consist&#234;ncia com que os pacientes tomam seus medicamentos ao longo do tempo, enquanto a persist&#234;ncia se refere a quanto tempo eles continuam o tratamento sem interrup&#231;&#227;o. Medicamentos para baixar o colesterol, particularmente estatinas, s&#227;o amplamente usados para reduzir o risco cardiovascular, mas a n&#227;o ades&#227;o continua sendo uma barreira para sua efic&#225;cia total.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
    <p>V&#225;rios fatores contribuem para a baixa ades&#227;o ao tratamento do colesterol alto, incluindo muitos pacientes que lutam para aderir ao tratamento porque o colesterol alto &#233; frequentemente assintom&#225;tico. Sem efeitos imediatos, os pacientes podem n&#227;o reconhecer a import&#226;ncia do uso consistente de medicamentos. As estatinas, os medicamentos mais comumente prescritos para baixar o colesterol, podem causar efeitos colaterais, como dores musculares, o que pode desencorajar os pacientes a continuar a terapia. O custo dos medicamentos, particularmente para pacientes de baixa renda, pode levar &#224; descontinua&#231;&#227;o ou racionamento do tratamento.<sup><xref ref-type="bibr" rid="B3">3</xref></sup></p>
    <p>Os farmac&#234;uticos desempenham um papel crucial na melhoria da ades&#227;o &#224; medica&#231;&#227;o. Sua posi&#231;&#227;o &#250;nica na &#225;rea da sa&#250;de permite que eles forne&#231;am atendimento personalizado ao paciente, monitorem o uso da medica&#231;&#227;o e ofere&#231;am conselhos pr&#225;ticos para abordar preocupa&#231;&#245;es comuns, como efeitos colaterais ou a complexidade dos esquemas de dosagem.<sup><xref ref-type="bibr" rid="B4">4</xref></sup></p>
    <p>Outra estrat&#233;gia eficaz para melhorar a ades&#227;o &#233; a dispensa&#231;&#227;o de medicamentos em volumes maiores, particularmente por meio de sistemas de sa&#250;de p&#250;blicos ou privados. Quando os pacientes recebem seus medicamentos em um suprimento maior, eles t&#234;m menos probabilidade de perder doses devido a desafios log&#237;sticos ou &#224; inconveni&#234;ncia de visitas frequentes &#224; farm&#225;cia.</p>
    <p>Um dos principais motivos para a descontinua&#231;&#227;o &#233; ficar sem medica&#231;&#227;o. Quando os medicamentos s&#227;o dispensados em pequenas quantidades, os pacientes precisam reabastec&#234;-los com frequ&#234;ncia, o que aumenta as chances de doses perdidas. Ao fornecer volumes maiores de medica&#231;&#227;o, como um suprimento para 90 dias em vez de um suprimento para 30 dias, os sistemas de sa&#250;de podem ajudar a reduzir essas interrup&#231;&#245;es e promover a persist&#234;ncia a longo prazo.</p>
    <p>Em muitos pa&#237;ses, o custo dos medicamentos &#233; uma barreira significativa &#224; ades&#227;o. Ao dispensar medicamentos em quantidades maiores, os sistemas de sa&#250;de p&#250;blicos e privados podem oferecer economia de custos aos pacientes, reduzindo a despesa geral do tratamento. A dispensa&#231;&#227;o em massa pode levar a economias de escala, reduzindo o custo por unidade dos medicamentos e tornando-os mais acess&#237;veis para os pacientes, especialmente aqueles com recursos financeiros limitados.</p>
    <p>Receber medicamentos em volumes maiores reduz a carga sobre os pacientes de visitar farm&#225;cias com frequ&#234;ncia, particularmente para aqueles em &#225;reas rurais ou carentes, onde o acesso a instala&#231;&#245;es de sa&#250;de pode ser limitado. Essa conveni&#234;ncia aumentada pode ter um impacto substancial na ades&#227;o, pois os pacientes t&#234;m menos probabilidade de esquecer ou atrasar as recargas.</p>
    <p>Quando os pacientes recebem um suprimento maior de medicamentos, isso refor&#231;a a ideia de que o tratamento &#233; um compromisso de longo prazo. Isso pode mudar sua mentalidade de ver o medicamento como uma solu&#231;&#227;o de curto prazo para entender que o uso consistente e de longo prazo &#233; cr&#237;tico para controlar seus n&#237;veis de colesterol e prevenir complica&#231;&#245;es cardiovasculares.</p>
    <p>No sistema de sa&#250;de brasileiro, esfor&#231;os recentes para aumentar o fornecimento de medicamentos aos pacientes por meio de programas p&#250;blicos t&#234;m produzido resultados promissores. O estudo dos ABC Cardiol destaca como essas iniciativas est&#227;o ajudando a melhorar as taxas de ades&#227;o entre a popula&#231;&#227;o.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Ao tornar os medicamentos mais acess&#237;veis e baratos, o Brasil fez avan&#231;os significativos no enfrentamento da quest&#227;o da n&#227;o ades&#227;o, particularmente em &#225;reas rurais onde os pacientes enfrentavam anteriormente desafios para obter recargas regulares.</p>
    <p>A decis&#227;o do governo de fornecer medicamentos em quantidades maiores por meio de seu sistema de sa&#250;de p&#250;blica tamb&#233;m aliviou alguns dos encargos financeiros dos pacientes, melhorando as taxas de persist&#234;ncia. Como resultado, mais pacientes est&#227;o permanecendo em seus tratamentos de redu&#231;&#227;o de colesterol por per&#237;odos mais longos, reduzindo seus riscos de eventos cardiovasculares.</p>
    <p>Concluindo, melhorar a ades&#227;o, a conformidade e a persist&#234;ncia no tratamento do colesterol alto requer uma abordagem multifacetada que aborde as v&#225;rias barreiras que os pacientes enfrentam. O envolvimento de farmac&#234;uticos como participantes ativos no atendimento ao paciente pode aumentar significativamente a ades&#227;o por meio de educa&#231;&#227;o, aconselhamento e gerenciamento simplificado de medicamentos. Al&#233;m disso, dispensar medicamentos em volumes maiores, principalmente por meio de sistemas de sa&#250;de p&#250;blicos ou privados, pode reduzir interrup&#231;&#245;es no tratamento, diminuir custos e aumentar a conveni&#234;ncia para os pacientes. Ao implementar essas estrat&#233;gias, os provedores de sa&#250;de podem fazer um progresso significativo na melhoria dos resultados de sa&#250;de de longo prazo para pacientes com colesterol alto.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="other" id="fn1">
        <label>Minieditorial referente ao artigo:</label>
        <p>Colesterol N&#227;o Controlado em Indiv&#237;duos com Hipercolesterolemia Grave Acompanhados em um Programa de Avalia&#231;&#227;o da Sa&#250;de no Brasil</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santos</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Kashiwagi</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Cesena</surname>
              <given-names>FY</given-names>
            </name>
            <name>
              <surname>Assis</surname>
              <given-names>SRL</given-names>
            </name>
            <name>
              <surname>Nieri</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Minanni</surname>
              <given-names>CA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Uncontrolled Cholesterol in Individuals with Severe Hypercholesterolemia in a Health Evaluation Program in Brazil</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2024</year>
          <volume>121</volume>
          <issue>11</issue>
          <elocation-id>e20240116</elocation-id>
          <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20240116i">https://doi.org/10.36660/abc.20240116i</ext-link></comment>
        </element-citation>
        <mixed-citation>1 Santos RD, Kashiwagi NM, Cesena FY, Assis SRL, Nieri J, Minanni CA, et al. Uncontrolled Cholesterol in Individuals with Severe Hypercholesterolemia in a Health Evaluation Program in Brazil. Arq Bras Cardiol. 2024; 121(11):e20240116. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20240116i">https://doi.org/10.36660/abc.20240116i</ext-link>.</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Menditto</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Cahir</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Malo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aguilar-Palacio</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Almada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Persistence as a Robust Indicator of Medication Adherence-related Quality and Performance</article-title>
          <source>Int J Environ Res Public Health</source>
          <year>2021</year>
          <volume>18</volume>
          <issue>9</issue>
          <fpage>4872</fpage>
          <lpage>4872</lpage>
          <pub-id pub-id-type="doi">10.3390/ijerph18094872</pub-id>
        </element-citation>
        <mixed-citation>2 Menditto E, Cahir C, Malo S, Aguilar-Palacio I, Almada M, Costa E, et al. Persistence as a Robust Indicator of Medication Adherence-related Quality and Performance. Int J Environ Res Public Health. 2021;18(9):4872. doi: 10.3390/ijerph18094872.</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Xi</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Factors Influencing Clinical Pharmacists&#8217; Integration into the Clinical Multidisciplinary Care Team</article-title>
          <source>Front Pharmacol</source>
          <year>2023</year>
          <volume>14</volume>
          <fpage>1202433</fpage>
          <lpage>1202433</lpage>
          <pub-id pub-id-type="doi">10.3389/fphar.2023.1202433</pub-id>
        </element-citation>
        <mixed-citation>3 Wang C, Li M, Huang Y, Xi X. Factors Influencing Clinical Pharmacists&#8217; Integration into the Clinical Multidisciplinary Care Team. Front Pharmacol. 2023;14:1202433. doi: 10.3389/fphar.2023.1202433.</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leslie</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Gwadry-Sridhar</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Thiebaud</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>BV</given-names>
            </name>
          </person-group>
          <article-title>Calculating Medication Compliance, Adherence and Persistence in Administrative Pharmacy Claims Databases</article-title>
          <source>Pharmaceutical Programming</source>
        </element-citation>
        <mixed-citation>4 Leslie SR, Gwadry-Sridhar F, Thiebaud P, Patel BV. Calculating Medication Compliance, Adherence and Persistence in Administrative Pharmacy Claims Databases. Pharmaceutical Programming.</mixed-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="S1" xml:lang="en">
    <front-stub>
      <article-id pub-id-type="doi">10.36660/abc.20240652i</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Editorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Adherence, Compliance and Persistency in High Cholesterol Treatment</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-1027-6954</contrib-id>
          <name>
            <surname>Martinez</surname>
            <given-names>Tania L. R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c2"/>
        </contrib>
        <aff id="aff2">
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">BP - A Benefic&#234;ncia Portuguesa de S&#227;o Paulo, S&#227;o Paulo, SP &#8211; Brazil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c2"><label>Mailing Address:</label><bold>Tania Martinez</bold> &#8226; Rua Comandante Ismael Guilherme, 358 - Jardim Lusit&#226;nia. Postal Code <postal-code>04031-120</postal-code> - S&#227;o Paulo, SP - Brazil E-mail: <email>tamar@uol.com.br</email></corresp>
      </author-notes>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Adherence</kwd>
        <kwd>Compliance</kwd>
        <kwd>Persistence</kwd>
        <kwd>Cholesterol</kwd>
        <kwd>Treatment</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>Lack of adherence to cholesterol-lowering medications remains a critical issue in managing cardiovascular risk. Despite advancements in treatment, many patients fail to follow their prescribed regimens, leading to increased risks of heart attack, stroke, and other cardiovascular events. As described in the study,<sup><xref ref-type="bibr" rid="B1">1</xref></sup> adherence challenges in the Brazilian population illustrate a global problem. However, there are several promising strategies for increasing adherence, including the active involvement of pharmacists and the distribution of medications in larger volumes through public or private healthcare systems.</p>
      <p>Medication adherence, or the degree to which patients follow their prescribed regimens, is fundamental to achieving optimal health outcomes in chronic conditions like high cholesterol. Compliance is the consistency with which patients take their medication over time, while persistence refers to how long they continue treatment without interruption. Cholesterol-lowering drugs, particularly statins, are widely used to reduce cardiovascular risk, but non-adherence remains a barrier to their full effectiveness.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
      <p>Several factors contribute to poor adherence to high cholesterol treatment, including many patients who struggle to adhere to treatment because high cholesterol is often asymptomatic. Without immediate effects, patients may not recognize the importance of consistent medication use. Statins, the most commonly prescribed cholesterol-lowering drugs, can cause side effects such as muscle pain, which can discourage patients from continuing therapy. The cost of medications, particularly for low-income patients, can lead to discontinuation or rationing of treatment.<sup><xref ref-type="bibr" rid="B3">3</xref></sup></p>
      <p>Pharmacists play a crucial role in improving medication adherence. Their unique position in healthcare allows them to provide personalized patient care, monitor medication use, and offer practical advice to address common concerns such as side effects or the complexity of dosing schedules.<sup><xref ref-type="bibr" rid="B4">4</xref></sup></p>
      <p>Another effective strategy for improving adherence is the dispensation of medications in larger volumes, particularly through public or private healthcare systems. When patients receive their medication in a greater supply, they are less likely to miss doses due to logistical challenges or the inconvenience of frequent pharmacy visits.</p>
      <p>One of the primary reasons for discontinuation is running out of medication. When drugs are dispensed in small quantities, patients need to refill them frequently, which increases the chances of missed doses. By providing larger volumes of medication, such as a 90-day supply rather than a 30-day supply, healthcare systems can help reduce these interruptions and promote long-term persistence.</p>
      <p>In many countries, the cost of medications is a significant barrier to adherence. By dispensing medications in larger quantities, public and private healthcare systems can offer cost savings to patients, reducing the overall expense of treatment. Bulk dispensing can lead to economies of scale, lowering the per-unit cost of medications and making them more affordable for patients, especially those with limited financial resources.</p>
      <p>Receiving medications in larger volumes reduces the burden on patients to frequently visit pharmacies, particularly for those in rural or underserved areas where access to healthcare facilities may be limited. This increased convenience can have a substantial impact on adherence, as patients are less likely to forget or delay refills.</p>
      <p>When patients receive a larger supply of medication, it reinforces the idea that treatment is a long-term commitment. This can shift their mindset from seeing the medication as a short-term fix to understanding that consistent, long-term use is critical for managing their cholesterol levels and preventing cardiovascular complications.</p>
      <p>In the Brazilian healthcare system, recent efforts to increase the supply of medications to patients through public programs have yielded promising results. The study by ABC Cardiol<sup><xref ref-type="bibr" rid="B1">1</xref></sup> report underscores how these initiatives are helping to improve adherence rates among the population. By making medications more accessible and affordable, Brazil has made significant strides in tackling the issue of non-adherence, particularly in rural areas where patients previously faced challenges in obtaining regular refills.</p>
      <p>The government's decision to provide medications in larger quantities through its public health system has also alleviated some of the financial burdens on patients, improving persistence rates. As a result, more patients are staying on their cholesterol-lowering treatments for longer periods, reducing their risk of cardiovascular events.</p>
      <p>In conclusion, improving adherence, compliance, and persistence in high cholesterol treatment requires a multifaceted approach that addresses the various barriers patients face. The involvement of pharmacists as active participants in patient care can significantly enhance adherence through education, counseling, and simplified medication management. Additionally, dispensing medications in larger volumes, particularly through public or private healthcare systems, can reduce interruptions in treatment, lower costs, and increase convenience for patients. By implementing these strategies, healthcare providers can make meaningful progress in improving long-term health outcomes for patients with high cholesterol.</p>
    </body>
    <back>
      <fn-group>
        <fn fn-type="other" id="fn2">
          <label>Short Editorial related to the article:</label>
          <p>Uncontrolled Cholesterol in Individuals with Severe Hypercholesterolemia in a Health Evaluation Program in Brazil</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
